Introduction Introduction
The incidence of complete Achilles tendon rupture is 18 per 100 000 patient-years 1 and is usually diagnosed clinically by GPs. The extent of clinical misdiagnosis is unknown in Norway, but may be high. 2 This is important as delayed treatment has unfavourable consequences. 1, 3 We report how a GP, with no clinical ultrasound experience, recorded images with a pocket-sized ultrasound device (PSUD) under supervision to confirm a complete Achilles tendon rupture. This could present a new indication for GP ultrasound.
Case report
A 36-year-old man experienced acute pain above the right heel accompanied by an audible snap while sprinting. He immediately had difficulty walking and 3 hours later consulted an on-call GP. Posterior ankle swelling with a tender depression 3 cm proximal to the calcaneum was found. Active plantar flexion against resistance was weak and Simmonds-Thompson test was 'partially positive' on applying a strong calf-squeeze. Based on these findings, calf muscle rupture was diagnosed as the Achilles tendon was thought to be intact. The patient was advised to elevate the foot and wait 2 weeks for improvement. Two days later a second GP, who was aware of a history of an audible snap, considered complete tendon rupture and reexamined the patient. Findings included an absent right heel raise due to weakness, minimal active plantar flexion against gravity and lying prone, significant right ankle swelling without bruising, and an altered angle of declination. Palpation elicited no ankle bony tenderness, yet a painful gap was identified 6 cm proximal from the calcaneal attachment, along the line of the Achilles tendon. Simmonds-Thompson's test was clearly positive. The positive Simmond's triad indicated a clinical diagnosis of complete rupture of the Achilles tendon. A 3.4-8 MHz linear array probe PSUD (VScanÔ dual probe, GE Healthcare), set at a depth of 3.5 cm, was used under the supervision of a rheumatologist experienced in ultrasound. The tendon was enlarged from 1 cm to 6 cm above the calcaneal insertion, where a clear gap was seen ( Figure 1) . Two hours later a radiologist-performed ultrasound (LOGIQ E9Ô, GE Healthcare) and reported an enlarged distal tendon and a complete rupture at 5-6 cm from the calcaneal attachment, creating a 2.7 cm blood-filled gap ( Figure 2 ). Surgical exploration 8 days post-injury found a complete Achilles tendon rupture '5-10 cm above the ankle joint'.
Discussion
Tromsø Hospital serves a large area with a population of approximately 160 000. Between 2010-2014 an average of 21 patients per year were referred by their GP for suspected Achilles rupture.
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Introduction
Last summer our small medical team visited the Calais 'Jungle'. Since that time much has changed and the camp is being demolished and by the time this article is read, it will probably be long gone. Some youngsters are finally being brought to the UK under the 'Dubs' amendment. However, once this camp is cleared it will not solve the ongoing flight of refugees from war torn areas: other camps are already appearing.
July 2016
A young Afghan man caught his finger on a sharp point while trying to cross a barbed wire fence. The finger was partially degloved. He attended the local hospital, where they placed a few sutures, but now, 2 weeks later, the skin is necrotic and the underlying tissue looks infected. He is in danger of losing his finger. A middle-aged Sudanese man has been having rigors and is generally unwell. He says it is similar to when he last had malaria.
A young Ukrainian woman complains of lower back pain and urinary frequency. The paths of these three people may never have crossed; yet here they are, denizens of the Calais Jungle. They turn up to a makeshift primary care 'clinic' that we set up in the heart of the unofficial refugee camp one weekend in July 2016.
With only basic medical supplies, we are immediately challenged by what we see. How can we arrange secondary care for the young Afghan in danger of losing his finger? We try to persuade him to return to the original local hospital, but he is reluctant. It was not a good experience for him the first time round.
With the other two patients, it is easier. They can attend the Salam clinic run by a local association during weekdays. Later, we receive word that malaria has been confirmed in our Sudanese patient.
More people arrive, presenting with scabies, rat bites, tinea, chest infections, and wheezing from inhaling smoke from fires lit to cook and keep warm in their tents at night. We examine a severely malnourished 2-year-old boy. We meet several of the camp's 600 unaccompanied children, at grave risk of sexual exploitation. We learn that there is inadequate safeguarding in place to protect them. A young Eritrean man comes in worried about his eye. He has sustained direct ocular trauma from a rubber bullet, and will never see normally again out of that eye. We see haematomas from police batons, and hear about children being exposed to tear gas again and again ( Figure 1 ).
The reality
These are no ordinary patients. They have travelled far from home to escape war, poverty, and misery. They have endured personal odysseys to get here, experienced untold hardships, and suffered unimaginable privations. Many have survived the loss of their families, torture, and rape. Their journeys over, for the moment at least, they must make their homes in the Calais Jungle. Their new shelters are in many cases mere tarpaulin covers, and their new beds just rugs on the ground. They own next to nothing. There is little for them to do, besides use their ingenuity to cross the English Channel in search of a better life. They are vulnerable to exploitation, crime, injury, and disease. Potentially violent clashes with local police, with other ethnic groups resident in the Jungle, or local far Despite having high survival rates for many types of cancer, Sweden has poor survival rates for LC. 9 The relative 5-year survival rate for LC in Sweden is 18%. 10 The low survival rate is mainly due to late-stage diagnosis. More than 50% of all Swedish patients with LC are diagnosed at Stage IV, with a relative 5-year survival rate of 2.6%. However, when LC is diagnosed at Stage I, the relative 5-year survival rate is 63.8%. 10 In order to increase survival rates for patients with LC, the most important factor is being able to identify those with a potentially curable disease. There is value in identifying patients at Stage I-III, whose LC has yet not spread, because they, as a group, have a relative 5-year survival of 36.1% versus 2.6% for Stage IV cancer.
10
Screening of target groups has been discussed as a method for early diagnosis of LC. Low-dose computed tomography (LDCT) in a defined population of high-risk persons has shown high sensitivity and acceptable specificity.
11 Publications from different LC screening trials show that up to 70%
of screen-detected, non-small cell LCs were found in Stage I, compared to around 15% found in routine clinical care. 12 LDCT is currently being used as screening for LC in the US.
12
GPs are important in cancer diagnostics because in countries like Sweden, Norway, Denmark, and France, approximately 70-87% of patients with cancer are diagnosed in a primary care setting.
5,13-
15 Because Sweden possesses unique total population-based databases, a case-control study could be conducted using regional databases for healthcare and diagnostic imaging in combination with the national cancer register.
This study aimed to:
. identify the clinical features of nMLC in primary care before the diagnosis is made; and . validate the clinical features from the regional healthcare database with clinical features in GPs' referral letters for chest X-rays.
Method Study design
A total population-based, case-control study was designed, using the SCR and a regional healthcare database in Region Vä stra Gö taland (RVG), Sweden. This region, which has 1.6 million inhabitants, is situated in the south-west of the country. The SCR, which was established in 1958, is one of the oldest disease registers in the world and has high validity. 16 All physicians, including pathologists, in Sweden are obliged by law to report all incident cases of cancer in both living and deceased patients to the SCR. 17 Each patient has a unique personal identity number, which all Swedish residents acquire either at birth or when they immigrate to Sweden. The regional healthcare database was established in RVG in 2000. It covers all hospitals, specialised outpatient care centres, and all private and public primary healthcare centres. The database includes a place of residence, age, sex, healthcare contacts, and diagnostic codes for diagnoses and surgical procedures. 18 Physicians are obliged to enter codes for a patient's current diseases or symptoms into the patient's medical records at each consultation. The reimbursement system for primary care providers is based partly on the disease burden of the patients, which is identified by diagnostic codes reported to this database. 
21 Both publicly and privately-financed radiology clinics send information to this database.
Study population
All patients in the RVG with LC diagnosed in 2011 were identified from the SCR. As this study was total population-based, no sample size was calculated.
Patients and matched controls were investigated for primary care diagnostic profiles. The inclusion criteria were:
. being diagnosed in RVG with LC;
. being alive at the time of the cancer diagnosis;
. being aged 18 years; and . having visited the GP during the year before cancer diagnosis.
Individuals were excluded from participation if they:
. lacked controls;
. had a previous cancer diagnosis in the SCR (1991-2010) ; or . had a metastasised, Stage IV LC.
Patients with a previous cancer diagnosis registered in the SCR during the 20-year period before 2011 were deliberately omitted, to avoid consultations in primary care being a control or related to a previous cancer. The controls were selected from the regional healthcare database. They had the same inclusion criteria as the patients with cancer, with the exception of a cancer diagnosis. Only controls from RVG who had visited a GP in primary care between 1 January 2010 and 31 December 2011 were eligible. Four controls were matched to each case for age, sex, and primary care unit.
Data collection and study measurements
The unique personal identity numbers of both cases and controls were linked to the regional healthcare database. All the data concerning diagnoses and dates of consultations with a GP between 1 January 2010 and 31 December 2011 were collected. The data extracted included diagnostic codes according to the Swedish version of the ICD-10;
22 or the Classification of Diseases and Health Problems 1997 Primary Care (KSH97-P). This is an abbreviated version of ICD-10, adapted to Swedish primary care to facilitate diagnostic coding.
23,24
The unique personal identity numbers of cases were linked to the EIA database. GPs' referral letters for chest X-ray -containing detailed clinical information with risk factors, symptoms, and signs from physical examinations and pathological laboratory results -were retrieved either from the EIA database or other repositories.
Two medical oncologists and a GP, independently of each other, coded the clinical features in all the referral letters for chest X-ray, using the ICPC-2 codes because these are more symptom-based. Where the codes were not consistent between the three coders, a consensus was reached on the final coding. These codes were then compared with the ICD-10 diagnostic codes from medical records in the healthcare database. As the authors only had access to diagnostic codes, the referral letters provided the reasons for chest X-ray referrals. In addition, because a more symptom-based coding classification was used (ICP-2), a comparison was made between how well the clinical features in referral letters corresponded to the clinical features coded in a less symptom-based classification (ICD-10) in the regional healthcare database.
Diagnostic codes
All the diagnostic codes registered when patients with cancer and their controls consulted their GP during the year preceding their cancer diagnosis were studied. Because >6000 different diagnostic codes were received for patients with nMLC, the number was reduced by merging the four-character diagnostic codes to the closest three-character diagnostic codes, according to clinical relevance. 15 Finally, 575 codes remained that had occurred in 1% of either cases or controls.
Data analyses
The 575 diagnostic codes were used as variables for univariable conditional logistic regression. Those found to be associated with cancer entered multivariable analyses, after which a list of statistically significant variables associated with LC was compiled. All analyses were performed using the statistical software R (version 3.0.1).
Results

Cases and controls
In total, 373 patients with LC were identified in the SCR. Of these, 132 patients had Stage I-III (35%) non-metastatic cancer, and the remaining 241 patients had Stage IV (65%). Although four controls had been matched to each case, 20 had died before their case was assigned a cancer diagnosis, so a total of 1472 controls were generated. The characteristics of the study sample is shown in Table 1 .
The disease burden for cases and controls was similar regarding the median number of unique diagnostic codes in the year before cancer diagnosis. Data retrieved from the regional database for radiology information (EIA) showed that 151 (40%) out of 373 patients with LC had been referred by a GP for a first chest X-ray in the year prior to cancer diagnosis ( Figure 1) . Hence, the majority of patients (51%) had been referred for chest X-ray by physicians in secondary care.
Variables
After the univariable conditional regression was done, there were 15 significant variables left (P<0.05) for patients with non-metastatic cancer and 23 for patients with metastatic cancer. The variables with an odds ratio of >1.5 are presented in Table 2 . After multivariate conditional regression, several significant variables were found to be independently associated with nMLC, but because there were too few cases for each combination of features, no calculation of positive predictive values could be performed. Even though all the patients included in this study consulted a GP in the year prior to their LC diagnosis, there were differences in their diagnostic profile depending on whether they had been referred for their first chest X-ray by their GP or from secondary care ( Table 3 ). In total, 40% of the patients referred for their first chest X-ray from primary care had nMLC, compared to 30% of those referred from secondary care. The clinical features were 2.7 times more frequent (337 versus 126) in referral letters for chest X-ray than the corresponding features in the healthcare database ( Table 4) . Age >80 years, n (%) 48 (13) 184 ( 
Discussion Summary
The study identified 12 features that were associated with nMLC, of which eight were also in common with metastatic LC. The features with the highest OR for nMLC were vitamin B12 deficiency anaemia, dyspnoea, and chronic bronchitis. Clinical features that were GPs' reasons for request for chest X-ray were almost three times more frequent in referral letters compared to the corresponding diagnostic codes in the medical records. 
Strengths and limitations
The main strength of this study is that it is total population-based. All patients with cancer were identified through the SCR, so there is no selection bias and the completeness of the register is very high. 16 The study looked at the clinical features presented during the year before LC diagnosis, because knowing these has major consequences for timelier and earlier LC diagnosis, which in turn affects prognosis. The use of diagnostic codes is another strength of the study. However, this could also be considered a limitation because not all the symptoms for which patients consulted a GP would be recorded as a diagnostic code in their medical record, as other fields of research in primary care databases have shown.
25
Most cancer symptoms occur 3-6 months before the cancer diagnosis, but a longer time than the one used in this study may be needed for observation. 26 The lack of laboratory results to validate the diagnoses of vitamin B12 deficiency anaemia, which had the strongest association with nMLC is another limitation. The absence of smoking status of patients with cancer is a limitation too, as the symptomatology of smokers has more severe implications than that of non-smokers.
27
Another limitation is that the authors were unable to design a risk assessment tool for nMLC in primary care. This is due either to the lack of a large enough sample, resulting in the inability to capture combinations of features, or to a truly low frequency of combination of features in the nonmetastatic population, which may not be detected even with a larger sample size. The low prevalence of clinical features in the regional healthcare database in comparison to clinical features in referral letters for X-ray is probably due to the former consisting mainly of diseases and the latter of symptoms. Another explanation could be that the reimbursement system for primary care providers is partly based on the disease burden of the patients, which favours disease codes over symptom codes.
Comparison with existing literature
To the authors' knowledge, this is the first study to present the clinical features of LC in patients with a non-metastatic disease. This is also the first study to present vitamin B12 deficiency anaemia as being a risk marker for nMLC. Perhaps this finding is a paraneoplastic phenomenon. However, previously published studies have shown that individuals with vitamin B12 deficiency anaemia are at increased risk for other cancers, such as gastric cancers and blood malignancies.
28,29 A recent systematic review from the UK has suggested that patients with thrombocytosis in primary care have an increased risk of several cancers, among them LC, which this study was unable to show as it lacked data on blood test results. 30 Another UK study from primary care has reported association with LC in the first year after presentation with back problems, which is in line with this study's findings. 31 In this study, the clinical information in referral letters for chest X-ray was extensive, in contrast to what has been reported in the literature.
32
A Danish study showed that patients with LC and chronic obstructive pulmonary disease (COPD) had more contacts in primary care in the 11 months prior to diagnosis than did patients with LC but without COPD. Thus, having COPD can mask symptoms of LC.
33 This is in line with the findings presented here, that COPD is a risk marker in patients with both non-metastatic and metastatic LC. Research An LC assessment tool for primary care has been developed and implemented in the UK. 27, 34 As this study did not result in a scoring instrument for LC, the results presented here are not easily comparable. The UK assessment tool makes no distinction between features depending on tumour stages. Compared to the UK study that found nine clinical features associated with LC, the present authors found only two in common with the nMLC group: dyspnoea and cough. In this study, haemoptysis was only associated with metastatic LC. QCancerÒ is another risk prediction algorithm. 35, 36 It is designed to estimate the 10-year risk of having 11 common cancers, including LC, and is based on both symptoms and risk factors. The symptoms studied were mostly 'red flag' symptoms and risk factors associated with LC. The tumour stages at diagnosis were not recorded, and there was no evidence as to whether use of the tool was likely to lead to identification of LC at an earlier stage. The clinical features presented in this study are the result of all symptoms and diseases being registered as diagnostic codes in general practice, and not just features that have been reported to be associated with LC in other studies. A large UK study has developed and validated a risk prediction model for LC, using a combination of patients' sociodemographic and early clinical features identified 4-12 months before diagnosis.
37 Again, the study was hard to compare with this one, as the clinical features were not associated with different tumour stages. The symptoms cough, dyspnoea, chest infections, and lower respiratory tract infections had similar OR as in this study, while haemoptysis had an OR twice as large compared to that in the present study's findings.
A recently published systematic review of risk prediction tools for patients with LC based on UK primary care data compared five different tools. 38 There was not sufficient evidence to recommend any of them because of the lack of external validation, evaluation in clinical practice, and cost impact. Also, none of the tools differentiated between symptoms depending on tumour stage. Existing risk prediction tools are not designed for identification of early-stage LC. However, LC screening of high-risk target groups with LDCT has shown many promising results in the detection rate of early-stage LC. This screening has been implemented in the US, but the results have been discouraging so far, because <4% of the eligible 6.8 million smokers in the US have received LDCT screening.
39
Implications for research
Patients with nMLC cannot be easily identified by symptoms. However, this study showed that referrals for chest X-ray from primary care resulted in a detection rate of 40% of patients with nMLC.
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